ARCHIVES

Legacy CEO Cheryl Healton says foundation could serve as funder for research on “potentially reduced-exposure products.”

This article is from The Cancer Letter archive.

Vol. 30 No. 41 | October 29, 2004

Download PDF Visit The Full Archive

Related Articles

Xeloda As Effective As 5-FU/LV, Five-Year Survival Data Show

September 28, 2007

In Brief: NIH AIDS William Paul To Step down; Aldige to Lead NCCR; Rimer Joins NCI

October 10, 1997

Season’s Greetings from the Cancer Letter

December 17, 1999

Georgetown Sponsors Oncology Agent Development Meeting

February 21, 2003

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

June 21, 2002

NCI Would Get More Money For AIDs Under Heckler Proposal, But Most Would Come Out Of Construction

August 2, 1985